The hormone replacement therapy market is expected to expand at a CAGR of 3.5%. The market value is projected to increase from US$ 16,825.2 million in 2024 to US$ 23,729.6 million by 2034. The hormone replacement therapy industry share was valued at US$ 15,976.9 million at the end of 2023.
Attributes | Details |
---|---|
Estimated Market Size, 2024 | US$ 16,825.2 million |
Expected Market Share, 2034 | US$ 23,729.6 million |
Value CAGR (2024 to 2034) | 3.50% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Attributes | Details |
---|---|
Hormone Replacement Therapy Market Value (2019) | US$ 13,059.1 million |
Hormone Replacement Therapy Market Size (2023) | US$ 15,976.9 million |
Historical CAGR % (2019 to 2023) | 4.1% |
The hormone replacement therapy (HRT) market expanded at a CAGR of 4.1% from 2019 to 2023. Meanwhile, the market surged from US$ 13,059.1 million in 2019 to US$ 15,976.9 million in 2023. The market is driven by a robust healthcare system in developed countries and increasing medical tourism. Other leading factors that have reinforced market competition in the previous period include:
From 2024 to 2034, the market is projected to register a CAGR of 3.5%. The market is projected to capture a market size of US$ 16,825.2 million in 2024. By 2034, the market valuation is anticipated to be US$ 23,729.6 million. Top factors that are contributing to market growth are as follows:
Historical CAGR % (2019 to 2023) | 4.1% |
---|---|
Forecast CAGR % (2024 to 2034) | 3.5% |
In this segment, related markets of hormone replacement therapy are considered and analyzed. The other two markets for this study are the anti-osteoporosis therapy and fracture healing market and the breast cancer drug market.
The anti-osteoporosis therapy and fracture healing market is projected to expand at a moderate pace in the next ten years. Rising osteoporosis cases due to low bone mass promote these therapies' sales. In addition, key players are investing in innovation and new product launches to circulate more effective medications.
Growth of the breast cancer drug market is estimated to record a CAGR of 1.1% through 2034. Poor lifestyle choices are increasing the risks of breast cancer. Governments and NGOs are coming together to provide financial assistance to breast cancer patients, thus increasing sales of breast cancer drugs.
Hormone Replacement Therapy Market:
Attributes | Hormone Replacement Therapy Market |
---|---|
CAGR (2024 to 2034) | 3.5% |
Growth Factor | Growing demand for advanced patient care. |
Future Opportunities | Increasing funding by key players for research and development activities. |
Market Trends | Changing perception of HRT in medical societies. |
Anti-osteoporosis Therapy and Fracture Healing Market:
Attributes | Anti-osteoporosis Therapy and Fracture Healing Market |
---|---|
CAGR (2024 to 2034) | 4.8% |
Growth Factor | Rising healthcare expenditure in rapidly growing economies is raising the growth of the anti-osteoporosis therapy and fracture healing market. |
Future Opportunities | Leading players are prioritizing the creation of advanced products that are convenient to use and provide improved efficacy. |
Market Trends | Surging preference for non-invasive therapies. |
Breast Cancer Drug Market:
Attributes | Breast Cancer Drug Market |
---|---|
CAGR (2024 to 2034) | 1.1% |
Growth Factor | The development of advanced technology to detect breast cancer early on is raising demand for breast cancer drugs. |
Future Opportunities | Numerous governments and NGOs are organizing campaigns to disseminate awareness and financial aid to breast cancer patients. |
Market Trends | Ongoing research studies to bring advancements in the field of breast cancer. |
Leading Therapy Area | Estrogen Replacement Therapy |
---|---|
Value Share % (2024) | 38.9% |
The estrogen replacement therapy (ERT) segment is projected to account for a share of 38.9% in 2024. The segment is anticipated to capture an increased female population experiencing falling levels of estrogen and progesterone. Change in hormone secretion, typically caused during menopause, also derails the quality of life. Thus, patients of menopause are being prescribed estrogen replacement therapy to reduce impact of falling hormones.
This segment is further projected to grow due to several women entering the stage of menopause. Increasing demographic of menopausal women is expected to raise the consumption of ERT in the next ten years.
Leading Dosage Form | Oral Tablets/Capsules |
---|---|
Value Share % (2024) | 43.2% |
Oral tablets/capsules segment is anticipated to acquire a share of 43.2% in 2024. Oral dosage is gaining significant traction due to its convenience. Several patients, especially those who are senior or have a hard time with other routes of administration, prefer oral medications.
Their higher uptake also hinges on the fact that it is cost-effective and demonstrates effective absorption. Additionally, oral capsules or tablets have formed a well-established safety profile over the years. Thus increasing its acceptance among doctors and patients.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Country | The United States |
---|---|
Forecast CAGR % (2024 to 2034) | 1.6% |
The hormone replacement therapy market in the United States is anticipated to register a CAGR of 1.6% through 2034. Sluggish adoption of this medication points toward market maturity attained by the United States. To break into this country, key players are projected to strive forward massively. Key factors propelling growth in the United States are as follows:
Country | The United Kingdom |
---|---|
Forecast CAGR % (2024 to 2034) | 2.3% |
As per recent market estimates, the United Kingdom is assessed to expand at a CAGR of 2.3% through 2034. The country is anticipated to be driven by:
Country | Germany |
---|---|
Forecast CAGR % (2024 to 2034) | 2.1% |
In Germany, the demand for hormone replacement therapies is anticipated to increase at a CAGR of 2.1% through 2034. The market is driven by the following factors:
Country | China |
---|---|
Forecast CAGR % (2024 to 2034) | 4.5% |
As per the latest market research by FMI analysts and industry experts, the China hormone replacement therapy market is projected to expand at a CAGR of 4.5% through 2034. The following factors are supporting market growth in the country:
These aforementioned factors are projected to consolidate the market position in China. Constant innovations and target markets in China are anticipated to propel significant market expansion.
Country | India |
---|---|
Forecast CAGR % (2024 to 2034) | 5.2% |
Manufacturers are expected to obtain significant growth opportunities in India. FMI analysts have estimated that the market in India is going to rise at a CAGR of 5.2% through 2034. Crucial factors that are augmenting the uptake of hormone replacement therapy in India are as follows:
Key players are strategically collaborating within the hormone replacement therapy market to position themselves for success. Players are further investing in research and development activities to enhance the efficacy of these therapies and increase consumer confidence. Additionally, market participants are attempting to obtain patents and product approvals to expand their portfolio.
Market participants are further partnering with other players or social media influencers to increase awareness about postmenopausal problems. This is anticipated to raise consumer knowledge about various options available to them.
To increase product adoption, manufacturers are launching hormone replacement products in user-friendly, distinct formats like patches and pills. Market leaders are also traversing boundaries to reach more customers.
New Developments Giving Shape to the Hormone Replacement Therapy Market
The hormone replacement therapy market is projected to be worth US$ 16,825.2 million in 2024.
The market is predicted to expand at a CAGR of 3.5% through 2034.
The market is anticipated to account for US$ 23,729.6 million by 2034.
India is predicted to provide high growth opportunities.
Estrogen replacement therapy acquired a leading share of the market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Therapy Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Therapy Type, 2019 to 2023 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy Type, 2024 to 2034 5.3.1. Estrogenic Replacement Therapy 5.3.2. Growth Hormone Replacement 5.3.3. Dopamine Agonist 5.3.4. Somatostatin Analogues 5.3.5. Thyroid Hormone Replacement 5.3.6. Tablets 5.3.7. Capsules 5.3.8. Injections 5.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Therapy Type, 2024 to 2034 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2019 to 2023 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2024 to 2034 6.3.1. Cancer 6.3.2. Menopause 6.3.3. Hypopituitarism 6.3.4. Hypothyroidism 6.3.5. Others 6.4. Y-o-Y Growth Trend Analysis By Application, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Application, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2019 to 2023 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2024 to 2034 7.3.1. Hospital Pharmacies 7.3.2. Retail Pharmacies and Drugstores 7.3.3. Compounding Pharmacies 7.3.4. E-commerce 7.3.5. Others 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2019 to 2023 7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2024 to 2034 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Therapy Type 9.2.3. By Application 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Therapy Type 9.3.3. By Application 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Therapy Type 10.2.3. By Application 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Therapy Type 10.3.3. By Application 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. UK 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Therapy Type 11.2.3. By Application 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Therapy Type 11.3.3. By Application 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Therapy Type 12.2.3. By Application 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Therapy Type 12.3.3. By Application 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Therapy Type 13.2.3. By Application 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Therapy Type 13.3.3. By Application 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Therapy Type 14.2.3. By Application 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Therapy Type 14.3.3. By Application 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Therapy Type 15.2.3. By Application 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Therapy Type 15.3.3. By Application 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2023 16.1.2.1. By Therapy Type 16.1.2.2. By Application 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2023 16.2.2.1. By Therapy Type 16.2.2.2. By Application 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2023 16.3.2.1. By Therapy Type 16.3.2.2. By Application 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2023 16.4.2.1. By Therapy Type 16.4.2.2. By Application 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2023 16.5.2.1. By Therapy Type 16.5.2.2. By Application 16.5.2.3. By Distribution Channel 16.6. UK 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2023 16.6.2.1. By Therapy Type 16.6.2.2. By Application 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2023 16.7.2.1. By Therapy Type 16.7.2.2. By Application 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2023 16.8.2.1. By Therapy Type 16.8.2.2. By Application 16.8.2.3. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2023 16.9.2.1. By Therapy Type 16.9.2.2. By Application 16.9.2.3. By Distribution Channel 16.10. Poland 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2023 16.10.2.1. By Therapy Type 16.10.2.2. By Application 16.10.2.3. By Distribution Channel 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2023 16.11.2.1. By Therapy Type 16.11.2.2. By Application 16.11.2.3. By Distribution Channel 16.12. Czech Republic 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2023 16.12.2.1. By Therapy Type 16.12.2.2. By Application 16.12.2.3. By Distribution Channel 16.13. Romania 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2023 16.13.2.1. By Therapy Type 16.13.2.2. By Application 16.13.2.3. By Distribution Channel 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2023 16.14.2.1. By Therapy Type 16.14.2.2. By Application 16.14.2.3. By Distribution Channel 16.15. Bangladesh 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2023 16.15.2.1. By Therapy Type 16.15.2.2. By Application 16.15.2.3. By Distribution Channel 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2023 16.16.2.1. By Therapy Type 16.16.2.2. By Application 16.16.2.3. By Distribution Channel 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2023 16.17.2.1. By Therapy Type 16.17.2.2. By Application 16.17.2.3. By Distribution Channel 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2023 16.18.2.1. By Therapy Type 16.18.2.2. By Application 16.18.2.3. By Distribution Channel 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2023 16.19.2.1. By Therapy Type 16.19.2.2. By Application 16.19.2.3. By Distribution Channel 16.20. South Korea 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2023 16.20.2.1. By Therapy Type 16.20.2.2. By Application 16.20.2.3. By Distribution Channel 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2023 16.21.2.1. By Therapy Type 16.21.2.2. By Application 16.21.2.3. By Distribution Channel 16.22. South Africa 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2023 16.22.2.1. By Therapy Type 16.22.2.2. By Application 16.22.2.3. By Distribution Channel 16.23. Israel 16.23.1. Pricing Analysis 16.23.2. Market Share Analysis, 2023 16.23.2.1. By Therapy Type 16.23.2.2. By Application 16.23.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Therapy Type 17.3.3. By Application 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Eli Lilly and Company 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Pfizer, Inc. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. AbbVie, Inc 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Novo Nordisk A/S 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Merck KGaA 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Mylan N.V 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Bayer Healthcare 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. F. Hoffmann-La Roche Ltd. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Teva Pharmaceuticals 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Endo International 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Healthcare
February 2021
REP-GB-1008
May 2023
252 pages
Explore Healthcare Insights
View Reports